Jump to content

Pathology Leading to Amputation

Original Editor - Maria Abela  as part of the World Physiotherapy Network for Amputee Rehabilitation Project

Top Contributors - Admin, Aicha Benyaich, Tarina van der Stockt, Jess Bell, Rachael Lowe, Stacy Schiurring, Kim Jackson, Tony Lowe, Sheik Abdul Khadir, Wanda van Niekerk, Lauren Lopez, 127.0.0.1 and Khloud Shreif  

Page Summary

  • Limb loss most commonly results from vascular disease, diabetes, trauma, infection, malignancy and congenital limb deficiency, with trauma more prevalent in low- and middle-income countries.
  • Peripheral artery disease (PAD) and diabetes are the most common causes of non-traumatic lower-limb amputations, and PAD reflects systemic atherosclerosis, signalling wider cardiovascular risk.
  • Falls (36.2%) and road traffic injury (15.7%) are the leading causes of traumatic amputation worldwide.
  • Diabetic foot ulceration, driven by motor, sensory and autonomic neuropathy, precedes approximately 80% of diabetes-related lower-limb amputations.

Introduction

Limb loss can arise from a range of underlying pathological processes, most commonly vascular disease, diabetes mellitus, trauma, infection, malignancy, and congenital limb deficiency.[1] Peripheral artery disease (PAD) and diabetes are the most common causes of non-traumatic lower-limb amputations,[2] and in high-income countries, they account for the large majority of lower limb amputations. Trauma-related amputation is more prevalent in low- and middle-income countries.[1][3]

Peripheral Artery Disease

Peripheral artery disease (PAD; also known as peripheral arterial disease or lower extremity occlusive disease) is narrowing or occlusion of the arteries supplying the limbs, most commonly the legs.[4] Fatty deposits (atheromas) accumulate within arterial walls, progressively narrowing the arterial lumen and restricting distal blood flow.[5][6] Onset is typically gradual and frequently asymptomatic despite significant underlying pathology. PAD is best understood as a manifestation of systemic atherosclerosis, a whole-body process that also affects the coronary and cerebral arteries, rather than a condition confined to the leg itself. This is why PAD is treated as a marker of overall cardiovascular risk, not just a local limb problem.[7][5]

To learn more about the peripheral vascular system, see: Cardiovascular System.

Example of physiological changes in blood vessels caused by PAD

Upper Limb PAD

PAD, and PAD-related amputation, predominantly affect the lower limb. Upper limb disease (most often affecting the subclavian, axillary, or brachial arteries) is considerably less common, as the upper limb's richer network of collateral vessels around the shoulder girdle provides better compensation for a narrowing artery.[8] A blood pressure difference of more than 15mmHg between the two arms is a recognised clinical pointer toward subclavian artery disease.[9] Non-traumatic upper limb acute limb ischaemia follows the same emergency principles described below for the lower limb, but occurs at only around one-fifth the incidence.[10]

Symptom: Intermittent (Arterial) Claudication

In lower-limb PAD, narrowed arteries can cause a mismatch between blood supply and demand. At rest, blood flow is typically adequate despite the arterial narrowing. However, with activity such as walking, the narrowed arteries cannot increase supply to meet the muscles' increased metabolic demand. This produces a reproducible cramping muscle pain that resolves within a few minutes of rest.[11] This pattern is called intermittent (arterial) claudication, and it is the characteristic early presentation of PAD.[12]


As PAD progresses and arterial narrowing becomes more severe, this supply-demand mismatch can persist even at rest, producing pain without exertion (pain at rest) and eventually tissue damage in the form of non-healing wounds, ulceration, or gangrene.[13] This tissue damage is the pathway by which PAD can lead to amputation.[12]

Clinical Pearl: Three Types of Claudication

"Claudication" simply means exertional pain that limits walking, but it has three distinct underlying causes, and telling them apart is important for both diagnosis and management.

  • Intermittent (arterial) claudication: caused by PAD. Reproducible calf, thigh, or buttock cramping brought on by walking a consistent distance, relieved simply by stopping and standing still; no need to sit or change position.[12] "Intermittent" and "arterial" are not two different conditions, but two ways of describing the same one. "Intermittent" refers to the characteristic on/off pattern of the pain (i.e. provoked by exertion, relieved by rest), while "arterial" (or "vascular") names the underlying cause: reduced blood flow from PAD. You will see both terms used interchangeably, and sometimes combined as "intermittent vascular claudication" in clinical literature and patient notes.
  • Neurogenic claudication: caused by lumbar spinal stenosis compressing nerve roots. It is characterised by buttock pain (unilateral or bilateral) and/or leg pain, weakness or heaviness. Symptoms worsen with standing, walking and spinal extension, and are relieved by flexion by either sitting down or bending forward (e.g. leaning on a shopping trolley) rather than by simply stopping.[14]
  • Venous claudication: a less common but important third type. It arises from chronic venous outflow obstruction (most often post-thrombotic syndrome after an iliofemoral DVT). It typically causes a bursting or tight cramping pain in the thigh, buttock or leg, with a slower build-up during exercise than the arterial type. Relief takes considerably longer, up to 15 minutes, and requires rest combined with leg elevation.[15] A history of iliofemoral DVT, oedema, and signs of venous congestion are useful pointers toward this cause.[16]


Because all three can present as reproducible exertional leg pain, a focused history helps narrow the differential diagnosis before further vascular or spinal investigation.


The following short video explains the difference between the three types of claudication. Intermittent claudication is discussed first.

[17]

Vascular Investigations for the Ischaemic Limb

Assessment begins with a clinical examination, including palpation of the lower limb pulses, followed by measurement of the Ankle-Brachial Index (ABI).

The Ankle-Brachial Index (or ABI, also known as the Ankle Brachial Pressure Index or ABPI) is the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. It is a quick, non-invasive assessment that can be performed at the bedside with a handheld Doppler, making it the most widely used first-line test for confirming and grading PAD severity.[16]

A low ABI may also help to identify broader cardiovascular and cerebrovascular risk,[18][19] not just limb-specific disease, so the result can prompt onward referral even when the patient's presenting complaint is unrelated to their legs. For rehabilitation professionals, it is a useful objective baseline: it can help clarify whether reduced exercise tolerance or leg pain is vascular in origin, and inform how aggressively to progress load-bearing activity.

ABI results are interpreted using the classification in Table 1.

Table 1. American College of Cardiology / American Heart Association and European Society for Vascular Surgery ABI classification guidelines[16][20]
ABI value Interpretation
1.00–1.40 Normal
0.91–0.99 Borderline
≤ 0.90 Abnormal, consistent with PAD
> 1.40 Non-compressible/calcified vessel

While a high ABI might intuitively read as reassuring, a result above 1.40 actually warrants caution. It usually reflects arterial calcification rather than genuinely healthy circulation, producing a falsely elevated reading, and should prompt a toe-brachial index instead. This is a clinically important point for rehabilitation professionals reviewing vascular status in people with diabetes, since a calcified-vessel result can easily be mistaken for good perfusion.

For the toe-brachial index (TBI), systolic pressure is measured at the great or second toe using a small toe cuff, with a Doppler, laser Doppler or photoplethysmography probe to detect the blood flow signal. This pressure is then divided by the higher of the two brachial systolic pressures. Toe arteries are less prone to the medial calcification that distorts ABI readings, so TBI is more reliable when ABI is falsely elevated or non-compressible.[21] A TBI of 0.70 or below is commonly used to indicate PAD, although thresholds vary between guidelines and studies.[22][23]

Arterial imaging is generally used when revascularisation is being considered. It may also be used when PAD is suspected clinically, but the ABI and other physiological tests are inconclusive.[16] Several imaging methods are available:

  1. Duplex ultrasound: non-invasive and does not require radiation or contrast.[16] It can locate areas of narrowing or occlusion and grade their severity.[24]
  2. CT angiography (CTA) and MR angiography (MRA): non-invasive, cross-sectional imaging. They are able to show the anatomy and severity of PAD in greater detail. Both carry risks related to contrast, and CTA also involves radiation exposure.[16]
  3. Catheter angiography: invasive and carries risks from radiation and contrast exposure, arterial injury and bleeding from placing the catheter. It is usually reserved for more severe PAD presentations where revascularisation is being considered.[16]

Management of PAD focuses first on guideline-directed management and therapy, including antiplatelet and statin therapy, blood pressure and diabetes control, and smoking cessation. This is combined with structured exercise therapy, which improves walking distance in people with claudication. Revascularisation is generally considered when symptoms remain limiting despite these measures, or in chronic limb-threatening ischaemia.[16] Revascularisation options for the ischaemic limb include:[16]

  1. Angioplasty/stenting: a balloon catheter is inserted and inflated at the site of stenosis or occlusion, often with stent placement.
  2. Endarterectomy: the artery is opened surgically and the plaque removed directly.
  3. Bypass grafting: a graft is used to route blood flow around a diseased segment of vessel.

Acute Limb Ischaemia

Acute limb ischaemia is a sudden reduction in limb perfusion that threatens limb viability within hours rather than years.[25] It is a vascular emergency and a distinct pathway to amputation (vs the chronic narrowing seen in PAD).

The two principal causes of acute limb ischaemia are arterial embolism (commonly cardiac in origin, such as from atrial fibrillation) and in-situ arterial thrombosis, typically at a site of pre-existing atherosclerotic plaque. Less common causes include popliteal aneurysm thrombosis, arterial trauma, and graft or stent occlusion.[25][26]

Severity is graded clinically using the Rutherford classification, which distinguishes a viable limb from one with threatened or irreversible ischaemia. This distinction determines whether revascularisation (via thrombolysis, thrombectomy, or open surgery) or primary amputation is appropriate. A limb with irreversible ischaemia cannot be saved, and delay risks systemic complications including hyperkalaemia and death.[25] Even with prompt treatment, acute limb ischaemia carries substantial risk. Published series report in-hospital amputation rates in the region of 6–8%, rising to around 11% at one year, and hospital mortality of roughly 6–9%.[25][27]

For rehabilitation professionals, the key distinguishing feature from chronic PAD-related amputation is the acuity and the correspondingly compressed timeframe, both for medical decision-making and, where amputation does occur, the patient's psychological adjustment.

Smoking

Smoking is an independent, modifiable risk factor for lower limb amputation and it is one of the strongest risk factors for developing PAD.[28] It also impairs wound healing, so it compounds risk in PAD, diabetic ulceration, and post-traumatic or post-surgical healing alike. Nicotine itself is a vasoconstrictor, reducing cutaneous blood flow and worsening tissue ischaemia.[29] Thromboangiitis obliterans (Buerger disease) is a peripheral occlusive, nonatherosclerotic, inflammatory vasculitis that is strongly associated with smoking.[30] It is most prevalent in men aged 40-45 and it accounts for a small proportion of major upper and lower limb amputations.[31]

Diabetes Mellitus and Diabetic Ulcers

Diabetes is a major, independent contributor to amputation risk.[32] The remaining limb is also at risk in people with diabetes, with around one in five having a contralateral amputation within five years of a first amputation.[33] This elevated risk arises through two interacting pathways. First, diabetes accelerates atherosclerosis and PAD.[34] Second, chronic hyperglycaemia damages nerves and small blood vessels, which can lead to foot ulceration.[35]

Most diabetes-related amputations occur in people with type 2 diabetes (DM2) because it is far more common, but type 1 diabetes (DM1) may carry a disproportionate amputation risk. A large US inpatient study found that patients with DM1 were independently more likely to present with chronic limb-threatening ischaemia and ulceration, and to undergo amputation, than those with DM2 once hospitalised with PAD. This is plausibly explained by disease duration: DM1 is typically diagnosed at a much younger age, so by any given point in adulthood a person with type 1 has typically had more years of hyperglycaemia. Duration of diabetes is itself one of the strongest known drivers of neuropathy and vascular complications.[36]

To learn more about DM1 and DM2, please see: Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2.

Diabetic foot ulcer

The pathway from hyperglycaemia to ulceration begins with peripheral neuropathy. Chronic hyperglycaemia, together with associated metabolic dysfunction, such as dyslipidaemia and impaired insulin signalling, activates multiple interacting pathways that cause progressive damage to peripheral nerves and their microvasculature.[37]

Neuropathy may involve motor, sensory and autonomic fibres, each contributing to ulceration through a different mechanism:

  • Motor neuropathy causes weakness and wasting of the intrinsic foot muscles, resulting in muscle imbalances across the foot. This produces structural deformities, such as claw toe or hammer toe. These create new, abnormal pressure points on the foot that are prone to skin breakdown under normal weight-bearing.
  • Loss of protective sensation means that minor trauma to the foot frequently goes unnoticed. Without pain to prompt rest or offloading, wounds can progress unchecked, particularly under repetitive pressure or shear forces during walking.
  • Autonomic neuropathy reduces sweating, leaving the skin dry and prone to fissuring. This creates a further point of entry for infection.

The combined effect of these three deficits is why people with diabetes have a high lifetime risk of developing a foot ulcer,[38] and why foot ulceration precedes approximately 80% of diabetes-related lower limb amputations.[39][40] Preventing foot ulceration is therefore central to amputation prevention in this population, through a multidisciplinary approach that includes structured foot care, glycaemic control, and ongoing monitoring for complications.[38]

Diabetic Charcot foot deformity

Charcot neuroarthropathy (also called neuropathic osteoarthropathy or Charcot foot) is a distinct diabetic complication that rehabilitation professionals should be able to recognise separately from straightforward ulceration, since it follows a different mechanical pathway and is frequently missed or misdiagnosed. It arises from a combination of peripheral neuropathy, repetitive unrecognised microtrauma, and neurovascular dysregulation that produce progressive bone and joint destruction, most often in the midfoot.[41][42] Onset is often insidious, presenting as a warm, swollen foot that is often painless (because of polyneuropathy).[43] It may be mistaken for cellulitis, gout, or osteomyelitis.[44]

Charcot neuroarthropathy substantially increases the risk of foot ulceration and amputation.[45] Outcomes are correspondingly serious: five-year mortality following diagnosis is around 30%; this rate largely reflects the burden of comorbidity in this population rather than the joint pathology itself.[45][46] Early recognition and prompt multidisciplinary referral are central to preventing progression to ulceration and amputation.[44]

Quick mention of the upper limb: The ulceration-to-amputation pathway described above is genuinely lower-limb-dominant, since it depends on the combination of insensate skin and repetitive weight-bearing pressure that has no direct upper limb equivalent. Diabetes does cause recognised upper limb musculoskeletal complications, most notably diabetic cheiroarthropathy (limited joint mobility of the hand, affecting a substantial proportion of patients with longstanding type 1 diabetes), but these are contracture and stiffness disorders rather than an ulceration or ischaemic pathway, and are not a recognised route to amputation in the way diabetic foot disease is.[47]

Trauma

Amputation may be needed immediately at the time of injury when a limb is too severely damaged to save. Alternatively, it may be delayed either because an initial attempt at reconstruction has failed to heal, or because, after assessment, reconstruction is judged likely to leave the patient with worse function than a well-fitted prosthesis would. Traumatic mechanisms include compound fracture, major vessel rupture, severe burns, blast injury, penetrating trauma, crush injury, and cold injury. Even minor trauma can precipitate amputation in a person with diabetes. Population density and natural disasters, particularly earthquakes, are also recognised contributors to amputation incidence.[48]

Global burden of disease data identify the leading causes of traumatic amputation worldwide as falls (36.2%), road traffic injury (15.7%), other transportation injury (11.2%), and mechanical forces (10.4%).[49]

Conflict-related amputation is a significant and growing global contributor.[50] Conflict and terrorism rose from the eighth to the fourth leading cause of amputation burden globally between 1990 and 2021.[51] Casualty data during active conflict are rarely centralised, so estimates should be treated as indicative. Independent estimates for the cumulative number of Ukrainians with amputations since 2022 range from the tens of thousands into six figures; clinicians and humanitarian organisations describe limb loss as one of the conflict's defining injury patterns, at a scale unseen in Europe since the First World War.[52][53] A similar pattern followed the Iraq and Afghanistan conflicts, where blast injury produced a substantial cohort of service personnel with multiple limb loss, often with concurrent traumatic brain injury and PTSD.[54]

Landmines and explosive remnants of war remain a persistent cause of limb loss in current and former conflict zones, with recorded casualties (people killed or injured) reaching 6,279 in 2024, the highest in four years. Civilians accounted for 90% and children nearly half.[55]

Frostbite is classified as either a traumatic or vascular cause of amputation depending on regional convention.[48]

Infections

Systemic bacterial infection can necessitate amputation both as definitive treatment and as a life-saving measure, particularly in previously healthy individuals. Relevant infections include meningococcal meningitis and septicaemia, staphylococcal and MRSA infection, and necrotising fasciitis. Amputation rates from infection are thought to be higher in lower-resource settings, plausibly reflecting reduced access to antibiotics and timely surgical care. Infection following joint replacement or other orthopaedic or vascular surgery is a further recognised cause.[48]

Tumours

Bone- and cartilage-forming malignancies (osteosarcoma and chondrosarcoma) are rare but clinically aggressive, often requiring extensive local or systemic treatment. Surgical management remains the mainstay of chondrosarcoma treatment.[56] The main treatment strategies for osteosarcoma are surgical resection, chemotherapy, targeted therapy, and radiotherapy.[57] Historically, amputation was the main surgical treatment for osteosarcoma of the limbs, but advances in surgical techniques and chemotherapy mean that limb salvage surgery is now the predominant approach, with amputation reserved for a smaller subset of cases.[58] Multiple amputations for malignancy are rare.[54]

Other Recognised Causes

The conditions above account for the substantial majority of amputations, but several less common pathways are worth recognising, since each presents differently and can otherwise be misattributed to a more familiar cause.

Condition Mechanism Clinical relevance to amputation
Sepsis-induced symmetrical peripheral gangrene (sometimes accompanied by purpura fulminans)[59][60]
  • Disseminated intravascular coagulation triggers microvascular thrombosis, typically in a symmetrical, acral distribution affecting distal limbs
  • Most often associated with severe bacterial sepsis (classically pneumococcal or meningococcal), though it also occurs after surgery or with malignancy
  • A rare but severe complication with mortality up to 25–40%
  • Among survivors, roughly half require amputation, and multi-limb amputation is common
Vasopressor-associated peripheral ischaemia[61]
  • High-dose vasopressor therapy during septic shock can cause intense peripheral vasoconstriction, contributing to (though not proven to independently cause) the same symmetrical gangrene process
  • This is an increasingly recognised iatrogenic contributor in ICU survivors
  • Case reports describe patients requiring amputation of two or more limbs following prolonged vasopressor use in critical illness
Vasculitis and connective tissue disease

(e.g. systemic sclerosis, ANCA-associated vasculitis)[62][63][64]

  • Chronic vascular inflammation and structural change (intimal proliferation, vasospasm, and thrombosis) compromise the digital and, less commonly, more proximal arterial supply
  • Raynaud's phenomenon is present in over 90% of systemic sclerosis patients and is a marker of the underlying vasculopathy
  • Digital ischaemia and ulceration are common in systemic sclerosis; amputation is a recognised, if less frequent, outcome in severe or overlap disease
Hair-thread tourniquet syndrome[65]
  • A hair or fine thread wraps tightly around a digit (occasionally the genitalia), most often in infants aged around two weeks to six months
  • Soft-tissue swelling progressively tightens the constriction, producing a compartment-syndrome-like ischaemic injury
  • An easily missed cause of unexplained digit swelling or erythema in an otherwise well infant
  • Delayed recognition can progress to tissue necrosis and autoamputation, or surgical amputation of the digit
Tight casts, splints, or circumferential dressings
  • Post-injury or post-surgical swelling beneath a rigid or tightly applied covering is not anticipated, or the covering is not loosened or split in time, producing a compartment-syndrome-like ischaemic injury distal to the constriction
  • A recognised, largely preventable iatrogenic cause
  • Underpins standard practice around splitting casts and close post-application neurovascular monitoring
Tourniquet misapplication

(surgical, first-aid, or military)

  • A pneumatic or improvised tourniquet applied for haemorrhage control or intraoperative field exposure is left in place beyond a safe time window, or applied with excessive pressure, causing sustained arterial occlusion
  • Rare in modern practice given standardised time limits and monitoring protocols, but a recognised cause of limb loss where evacuation or transport delays prolong application
  • Particularly documented in military and battlefield medicine literature
Constricting rings or jewellery
  • A ring or band becomes acutely tight around a digit, most often due to unanticipated soft-tissue swelling from trauma, infection, or allergic reaction, and is not removed in time
  • Usually managed successfully as an emergency (ring-cutting)
  • Amputation is a rare but reported outcome of delayed presentation

These last four causes can be grouped together as acquired constriction, distinct from the congenital constriction band syndrome discussed later on this page (see Congenital Limb Deficiency). Reliable population-level incidence data is not available for acquired constriction as a group; these are reported almost exclusively via individual case reports, small case series, and narrative reviews rather than epidemiological studies.

Amputations in Children

Paediatric limb loss falls into two categories: acquired amputation and congenital limb deficiency.[66]

Acquired Amputation

Acquired amputation in children results from severe infection, cancer, trauma, or vascular/neural abnormality, including cases where a congenital abnormality is later treated by conversion amputation. Surgical, rehabilitative, and prosthetic management broadly mirrors adult practice, with the important caveat that the child is still growing. Trauma is around three times more likely to cause amputation in children than other biological causes, most often related to power tools, vehicle collisions, lawnmowers, fireworks, farm equipment, or gunshot injury.[66]

Tumours. Bone malignancies such as Ewing sarcoma and osteosarcoma account for a small proportion of paediatric cancers overall, but treatment advances have substantially improved prognosis in recent decades. As survival has improved, an increasing number of childhood cancer survivors are living with the long-term physical and psychological consequences of limb loss.[3]

Emerging Risk: Youth-Onset DM2. Type 2 diabetes diagnosed in childhood or adolescence is not a traditional cause of paediatric amputation, but it represents an emerging risk pathway that rehabilitation professionals working with young adults should be aware of. Youth-onset DM2 has risen sharply in incidence in parallel with rising childhood obesity, and follows a more aggressive disease course than either adult-onset DM2 or DM1, with faster deterioration in insulin secretion and typically poorer glycaemic control.[67][68] Serious complications (e.g. dialysis, blindness, and amputation) have been shown to begin emerging within roughly 10 to 13 years of diagnosis, meaning some patients face these outcomes while still in their twenties.[68][69] This shifts the relevant clinical population for diabetes-related amputation prevention younger than has traditionally been assumed, with direct implications for when structured foot care and vascular monitoring should begin.

Congenital Limb Deficiency

Reported estimates of the overall incidence of congenital limb deficiency range from roughly 20 to 70 per 100,000 live births.[70] Multiple-limb involvement is possible but rare.[54] Where a residual limb requires surgical preparation for prosthetic use and weight-bearing, this is assessed on an individual basis.[66]

Recognised causes include teratogenic drug exposure (historically illustrated by thalidomide) and genetic/familial factors; recurrence risk rises substantially where a previous child was affected, particularly in combination with other congenital abnormalities or a family history of limb deficiency.[48]

A further recognised cause is constriction band syndrome (also termed amniotic band syndrome, or amniotic band sequence), in which fibrous strands from a ruptured amnion entangle a developing limb in utero. Where a band constricts tightly enough to compromise distal blood flow, this can result in anything from a shallow constriction ring to complete spontaneous intrauterine amputation of a digit or limb. Reported incidence varies considerably across studies, ranging from approximately 1 in 1,200 to 1 in 15,000 live births.[71][72] Unlike teratogenic exposure or genetic/familial causes, constriction band syndrome arises through a mechanical and vascular disruption of an otherwise normally developing limb, rather than a primary developmental abnormality. This distinction is clinically relevant, since it also means constriction band syndrome does not carry the same recurrence risk in future pregnancies as the genetic/familial causes above.

For congenital lower-limb deficiencies such as congenital fibular deficiency, the long-term treatment goal is to support development into an active adulthood with optimal function and minimal musculoskeletal pain. Surgical options include limb salvage or lengthening versus amputation, aimed at achieving equal limb length and a normal gait pattern, with or without a prosthesis.[73] Early amputation can achieve good functional outcomes, but the decision is individualised, depending on surgical judgement and informed parental understanding of the risks and benefits involved.[74]

The following video provides detailed information about paediatric limb deficiencies.

[75]

Resources

References

  1. ↑ 1.0 1.1 Alaseem A, Alanezi M, Alhuqbani MN, Aldosari ZA, Alkhunein F, Alyahya K, et al. Etiologies and trends in extremity amputations: a ten-year single-center experience. Healthcare (Basel). 2025 Sep 9;13(18):2256.
  2. ↑ Kaser S, Radlinger B, Blasinger J, Koellenberger N, Streitberger V, Kopp L, Bifano E, Aziz F, Sourij H, Goebel G, Klocker J. Non-traumatic lower-limb amputations: outcome, sex-differences, comorbidity patterns and temporal trends from 2006 to 2022. Journal of Clinical Medicine. 2025 Jun 6;14(12):4030.
  3. ↑ 3.0 3.1 Loucas CA, Brand SR, Bedoya SZ, Muriel AC, Wiener L. Preparing youth with cancer for amputation: A systematic review. Journal of psychosocial oncology. 2017 Jul 4;35(4):483-93.
  4. ↑ Mandaglio-Collados D, Marín F, Rivera-Caravaca JM. Peripheral artery disease: Update on etiology, pathophysiology, diagnosis and treatment. Med Clin (Barc). 2023 Oct 27;161(8):344-350. English, Spanish.
  5. ↑ 5.0 5.1 Zemaitis MR, Boll JM, Kato M, Golla MS. Peripheral arterial disease. InStatPearls [internet] 2026 Jan 31. StatPearls publishing.
  6. ↑ Roma P, Jill I. Atherosclerosis. InStatPearls [internet] 2023 August 8. StatPearls publishing.
  7. ↑ Eid MA, Mehta KS, Goodney PP. Epidemiology of peripheral artery disease. InSeminars in Vascular Surgery 2021 Mar 1 (Vol. 34, No. 1, pp. 38-46). WB Saunders.
  8. ↑ Al-Sharydah AM, AlZahrani KS, Alghanimi IA, AlAnazi MM, AlHarbi RE. Anatomical distribution patterns of peripheral arterial disease in the upper extremities according to patient characteristics: a retrospective cohort study. Vascular Health and Risk Management. 2023 Dec 31:871-83.
  9. ↑ Tran B. Assessment and management of peripheral arterial disease: what every cardiologist should know. Heart. 2021 Nov;107(22):1835-43.
  10. ↑ Huang D, Ruzicka J, León L, Ganti L. Acute upper extremity arterial occlusion diagnosed on POCUS in the emergency department. POCUS journal. 2023 Apr 26;8(1):25.
  11. ↑ Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2017 Dec 26;12(12):CD000990.
  12. ↑ 12.0 12.1 12.2 Patel SK, Surowiec SM. Intermittent Claudication. InStatPearls [internet] 2023 July 10. StatPearls publishing.
  13. ↑ Bethel M, Annex BH. Peripheral arterial disease: A small and large vessel problem. Am Heart J Plus. 2023 Mar 23;28:100291.
  14. ↑ Ammendolia C, Hofkirchner C, Plener J, Bussières A, Schneider MJ, Young JJ, et al. Non-operative treatment for lumbar spinal stenosis with neurogenic claudication: an updated systematic review. BMJ Open. 2022 Jan 19;12(1):e057724.
  15. ↑ Tsouknidas I, Charisis N, Eklof B, Labropoulos N. Venous Claudication: a Scoping Review of the Pathophysiology and Clinical Importance. Eur J Vasc Endovasc Surg. 2022 Nov;64(5):535-543.
  16. ↑ 16.0 16.1 16.2 16.3 16.4 16.5 16.6 16.7 16.8 Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, Chandra V, Drachman DE, Eaves JM, Ehrman JK, Evans JN. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jun 11;149(24):e1313-410.
  17. ↑ YouTube. Types Of Claudication | Learn With MedNuggets. Available from: https://www.youtube.com/watch?v=X0UzMyBDdp0 [last accessed 25 August 2026]
  18. ↑ Heald CL, Fowkes FG, Murray GD, Price JF; Ankle Brachial Index Collaboration. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: Systematic review. Atherosclerosis. 2006 Nov;189(1):61-9.
  19. ↑ Borooghani H, Orangi K, Bagher Zadi P, Asefi H, Arabi M. Ankle-brachial index as a predictor of cardiovascular and cerebrovascular events in hypertension: a systematic review. Res Heart Yield Transl Med. 2026;21(1):71-84.
  20. ↑ Nordanstig J, Behrendt CA, Baumgartner I, Belch J, Bäck M, Fitridge R, Hinchliffe R, Lejay A, Mills JL, Rother U, Sigvant B. European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication 5.
  21. ↑ Casanegra AI, Liedl DA, McCarter C, Shuja F, Wennberg PW. Toe-brachial index: utility, futility, and diagnostic criteria. Angiology. 2026 Feb;77(2):221-8.
  22. ↑ Høyer C, Sandermann J, Petersen LJ. The toe-brachial index in the diagnosis of peripheral arterial disease. Journal of vascular surgery. 2013 Jul 1;58(1):231-8.
  23. ↑ Tehan PE, Mills J, Leask S, Oldmeadow C, Peterson B, Sebastian M, Chuter V. Toe-brachial index and toe systolic blood pressure for the diagnosis of peripheral arterial disease. Cochrane Database Syst Rev. 2024 Oct 30;10(10):CD013783.
  24. ↑ Lunt MJ. Review of duplex and colour Doppler imaging of lower-limb arteries and veins. Journal of tissue viability. 1999 Apr 1;9(2):45-55.
  25. ↑ 25.0 25.1 25.2 25.3 Björck M, Earnshaw JJ, Acosta S, Gonçalves FB, Cochennec F, Debus ES, Hinchliffe R, Jongkind V, Koelemay MJ, Menyhei G, Svetlikov AV. Editor's choice–European Society for Vascular Surgery (ESVS) 2020 clinical practice guidelines on the management of acute limb ischaemia. European Journal of Vascular and Endovascular Surgery. 2020 Feb 1;59(2):173-218.
  26. ↑ Elgendy IY. Acute Limb Ischemia Interventions. Peripheral Vascular Disease and Interventions, An Issue of Interventional Cardiology Clinics: Peripheral Vascular Disease and Interventions, An Issue of Interventional Cardiology Clinics, E-Book. 2025 Mar 11;14(2):273.
  27. ↑ Baril DT, Ghosh K, Rosen AB. Trends in the incidence, treatment, and outcomes of acute lower extremity ischemia in the United States Medicare population. Journal of vascular surgery. 2014 Sep 1;60(3):669-77.
  28. ↑ Kim HK, Kim MS, Ahn S, Min S, Min SK, Ha J, Han A. Smoking behavior and major cardiovascular and limb events in patients with peripheral artery disease. JAMA Netw Open. 2026 Aug 3;9(8):e2629337.
  29. ↑ Bonilla J, Rodríguez-Reyes D, Serpa-Irizarry M, Díaz-Cortés H, Barreras F, Rivera-Barrios A. The impact of nicotine on wound healing: a comparative review of cigarettes, vaping, and nicotine patches with insights into pathophysiological mechanisms. Medical Research Archives. 2025;13(6).
  30. ↑ Seebald J, Gritters L. Thromboangiitis obliterans (Buerger disease). Radiol Case Rep. 2015 Jul 15;10(3):9-11.
  31. ↑ Barbara Engstrom and Catherine Van de Ven, 1999, Therapy for Amputees, 3rd Edition, Churchill Livingston ISBN: 978-0-443-05975-9
  32. ↑ Luo Y, Liu C, Li C, Jin M, Pi L, Jin Z. The incidence of lower extremity amputation and its associated risk factors in patients with diabetic foot ulcers: A meta-analysis. Int Wound J. 2024 Jul;21(7):e14931.
  33. ↑ Liu R, Petersen BJ, Rothenberg GM, Armstrong DG. Lower extremity reamputation in people with diabetes: a systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2021 Jun;9(1):e002325.
  34. ↑ Soyoye DO, Abiodun OO, Ikem RT, Kolawole BA, Akintomide AO. Diabetes and peripheral artery disease: A review. World J Diabetes. 2021 Jun 15;12(6):827-838.
  35. ↑ Kim J. The pathophysiology of diabetic foot: a narrative review. J Yeungnam Med Sci. 2023 Oct;40(4):328-334.
  36. ↑ Jain N, Agarwal MA, Jalal D, Dokun AO. Individuals with peripheral artery disease (PAD) and type 1 diabetes are more likely to undergo limb amputation than those with PAD and type 2 diabetes. Journal of clinical medicine. 2020 Aug 31;9(9):2809.
  37. ↑ Yang Y, Zhao B, Wang Y, Lan H, Liu X, Hu Y, Cao P. Diabetic neuropathy: cutting-edge research and future directions. Signal Transduct Target Ther. 2025 Apr 25;10(1):132.
  38. ↑ 38.0 38.1 Mendes JJ, Neves J. Diabetic foot infections: current diagnosis and treatment. Journal of Diabetic Foot Complications. 2012:26-45.
  39. ↑ Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic foot ulcers: a review. JAMA. 2023 Jul 3;330(1):62-75.
  40. ↑ Lim JZ, Ng NS, Thomas C. Prevention and treatment of diabetic foot ulcers. J R Soc Med. 2017 Mar;110(3):104-109.
  41. ↑ Rajbhandari S, Jenkins RD, Davies C, Tesfaye S. Charcot neuroarthropathy in diabetes mellitus. Diabetologia. 2002 Aug;45(8):1085-96.
  42. ↑ Trieb K. The Charcot foot: pathophysiology, diagnosis and classification. The bone & joint journal. 2016 Sep 1;98(9):1155-9.
  43. ↑ Rosskopf AB, Loupatatzis C, Pfirrmann CWA, Böni T, Berli MC. The Charcot foot: a pictorial review. Insights Imaging. 2019 Aug 5;10(1):77.
  44. ↑ 44.0 44.1 Bagheri K, Anastasio AT, Krez A, Siewny L, Adams SB. Charcot neuroarthropathy of the foot and ankle in the acute setting: an illustrative case report and targeted review. Western Journal of Emergency Medicine. 2023 Aug 30;24(5):921.
  45. ↑ 45.0 45.1 Cellier N. Management of hindfoot and ankle in Charcot arthropathy. EFORT Open Reviews. 2025 Jun 1;10(6):327-35.
  46. ↑ Stergioti A, Manganas K, Tzeravini E, Kosta O, Eleftheriadou I, Tentolouris A. Charcot neuro-osteoarthropathy in diabetes: implications for diabetic foot ulcers, amputations, and survival. The International Journal of Lower Extremity Wounds. 2025 Dec;24(4):781-8.
  47. ↑ Abdalla E, Gamar AM, Taha ZI, Alfatih M. Diabetic cheiroarthropathy in uncontrolled type 2 diabetes with positive anti-nuclear antibodies: a case report from Sudan. Annals of Medicine and Surgery. 2024 Mar 21;86(6):3631.
  48. ↑ 48.0 48.1 48.2 48.3 Barbara Engstrom and Catherine Van de Ven. Therapy for Amputees, 3rd ed. Churchill Livingstone; 1999. ISBN: 978-0-443-05975-9.
  49. ↑ McDonald CL, Westcott-McCoy S, Weaver MR, Haagsma J, Kartin D. Global prevalence of traumatic non-fatal limb amputation. Prosthet Orthot Int. 2021 Apr 1;45(2):105-114.
  50. ↑ Yuan B, Hu D, Gu S, Xiao S, Song F. The global burden of traumatic amputation in 204 countries and territories. Frontiers in public health. 2023 Oct 20;11:1258853.
  51. ↑ Cuan X, Zhang J, Lu Z, Cui F, Zhao C, Lu W, et al. Global epidemiology of amputation-related disability from 1990 to 2021: geographic variation and projections to 2050. J Cachexia Sarcopenia Muscle. 2026 Aug;17(4):e70356.
  52. ↑ Sullivan D. The War Wounded: A Doctor Reports 62 Miles From Ukraine's Front Lines. Think Global Health, 2025. Available at: https://www.thinkglobalhealth.org/article/the-war-wounded-a-doctor-reports-62-miles-from-ukraines-front-lines (last accessed 20 August 2026).
  53. ↑ Hope for Ukraine. Ukraine Amputation Crisis: Tens of Thousands Need Care. 2025. Available at: https://hfu.org/ukraine-amputation-crisis-rehabilitation-shortage/ (last accessed 28 August 2026).
  54. ↑ 54.0 54.1 54.2 Pasquina PF, Miller M, Carvalho AJ, Corcoran M, Vandersea J, Johnson E, Chen YT. Special considerations for multiple limb amputation. Current physical medicine and rehabilitation reports. 2014 Dec;2(4):273-89..
  55. ↑ International Campaign to Ban Landmines – Cluster Munition Coalition. Landmine Monitor 2025. Available at: https://icblcmc.org/our-impact/landmine-monitor-2025-civilian-landmine-casualties-escalate-while-five-countries-take-dangerous-step-away-from-humanitarian-mine-ban (last accessed: 28 August 2026).
  56. ↑ Wang X, Zhu K, Hu J, Zhang C. Advances and challenges in the treatment of osteosarcoma. Prog Biophys Mol Biol. 2025 Sep;197:60-74.
  57. ↑ Gazendam A, Popovic S, Parasu N, Ghert M. Chondrosarcoma: a clinical review. J Clin Med. 2023 Mar 26;12(7):2506.
  58. ↑ Evans DR, Lazarides AL, Visgauss JD, Somarelli JA, Blazer DG 3rd, Brigman BE, Eward WC. Limb salvage versus amputation in patients with osteosarcoma of the extremities: an update in the modern era using the National Cancer Database. BMC Cancer. 2020 Oct 14;20(1):995. d
  59. ↑ Davis MD, Dy KM, Nelson S. Presentation and outcome of purpura fulminans associated with peripheral gangrene in 12 patients at Mayo Clinic. Journal of the American Academy of Dermatology. 2007 Dec 1;57(6):944-56.
  60. ↑ Chen Y, Liu K, Xu X, Wu G, Zhu L, Zha J, Cheng C. Symmetrical peripheral gangrene caused by urosepsis: Case reports and literature review. Medicine. 2024 Oct 4;103(40):e39508.
  61. ↑ Ang CH, Koo OT, Howe TS. Four limb amputations due to peripheral gangrene from inotrope use–case report and review of the literature. International journal of surgery case reports. 2015 Jan 1;14:63-5.
  62. ↑ Schiopu E, Impens AJ, Phillips K. Digital ischemia in scleroderma spectrum of diseases. International journal of rheumatology. 2010;2010(1):923743.
  63. ↑ Önaloğlu Y, Gümüş ÖF, Karakılıç B, Özlük AV, Balcı EC, Talmaç MA, Civan M. Predictors of Reamputation in Patients With Advanced‐Stage Thromboangiitis Obliterans Ulcers: A Retrospective Cohort Study. International Wound Journal. 2026 Feb;23(2):e70853.
  64. ↑ Herrick AL, Oogarah PK, Freemont AJ, Marcuson R, Haeney M, Jayson MI. Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation. Annals of the rheumatic diseases. 1994 May;53(5):323-6.
  65. ↑ Arkoubi AY, Salati SA. Hair-thread tourniquet syndrome: a comprehensive review. Cureus. 2024 May 22;16(5).
  66. ↑ 66.0 66.1 66.2 Smith DG. Congenital limb deficiencies and acquired amputations in childhood, part 3. Motion. 2006;16(1):41-5.
  67. ↑ Lim LL, Jones S, Cikomola JC, Hivert MF, Misra S. Understanding the drivers and consequences of early-onset type 2 diabetes. The Lancet. 2025 Jun 28;405(10497):2327-40.
  68. ↑ 68.0 68.1 TODAY Study Group. Long-term complications in youth-onset type 2 diabetes. New England Journal of Medicine. 2021 Jul 29;385(5):416-26.
  69. ↑ Dart AB, Martens PJ, Rigatto C, Brownell MD, Dean HJ, Sellers EA. Earlier onset of complications in youth with type 2 diabetes. Diabetes care. 2014 Feb 1;37(2):436-43.
  70. ↑ Congenital Lower Limb Deficiency. PM&R KnowledgeNow. Available at: https://now.aapmr.org/congenital-lower-limb-deficiency/ (last accessed: 28 August 2026).
  71. ↑ Pape K, Gorla SR. Amniotic Band Syndrome. InStatPearls [internet] 2025 July 7. StatPearls publishing.
  72. ↑ Cignini P, Giorlandino C, Padula F, Dugo N, Cafà EV, Spata A. Epidemiology and risk factors of amniotic band syndrome, or ADAM sequence. Journal of prenatal medicine. 2012 Oct;6(4):59.
  73. ↑ Kaastad TS, Tveter AT, Steen H, Holm I. Physical function and health-related quality of life in young adults with unilateral congenital lower-limb deficiencies. Journal of children's orthopaedics. 2017 Oct;11(5):348-57.
  74. ↑ Calder P, Shaw S, Roberts A, Tennant S, Sedki I, Hanspal R, Eastwood D. A comparison of functional outcome between amputation and extension prosthesis in the treatment of congenital absence of the fibula with severe limb deformity. Journal of Children's Orthopaedics. 2017 Aug;11(4):318-25.
  75. ↑ YouTube. Limb Deficiencies | Global HELP Organization. Available from: https://www.youtube.com/watch?v=pUFSKYt-ACE [last accessed 28 August 2026]


Retrieved from "https://www.physio-pedia.com/w/index.php?title=Pathology_Leading_to_Amputation&oldid=384333"